Produced in collaboration with GBS | CIDP Foundation International
Support for this patient education program was provided by argenx, Pfizer, and UCB
Are you interested in learning more about clinical trial options for patients with CIDP or GBS? Tune in on 10/29 to hear from our multidisciplinary panel comprised of a CIDP-GBS representative, a person who has participated in a clinical trial, and a neurologist for this virtual education program. Additionally, in Part 4 of the program, you will hear from clinical trial researchers as they discuss ongoing clinical trials in CIDP and GBS.
The panelists will engage in a discussion about the role of clinical trials in improving individual and community health care as well as determining when a clinical trial is a viable option for patients with CIDP. The panel will also discuss the benefits of participating in a clinical trial and will provide a review of ongoing clinical trials in CIDP and GBS. Lastly, you will also hear from a clinical trial participant as they share their experience and insights into clinical trial participation.
This live, interactive program is broken into 4 parts:
- Part 1: The Role of Clinical Trials for CIDP
- Part 2: When a Clinical Trial is a Viable Option
- Part 3: The Benefits of Clinical Trials and How GBS-CIDP Foundation Can Help
- Part 4: Review of Ongoing Clinical Trials in CIDP and GBS
Jeffrey Allen, MD
Associate Professor, University of Minnesota
Executive Director, GBS/CIDP Foundation International
Lisa Butler is the executive director of the GBS/CIDP Foundation International in Narberth, Pennsylvania. Ms Butler has a 10-year career in marketing and event planning for nonprofit organizations. Before assuming her current position as executive director, she managed the Foundation’s marketing and development programs, and was recognized by Patient Services, Inc. (PSI) with the 2016 Extraordinary Support Award. Ms Butler first of learned of the Foundation in 1992 (prior to joining the staff in 2013) when her father-in-law was diagnosed with Guillain-Barre syndrome (GBS).Ten years later, her son, Stuart, was diagnosed with GBS. Following Stuart’s recovery, she became the parent liaison for the Foundation for “parents with children diagnosed with GBS”.
Elizabeth Thirtyacre, RN, BSN
CIDP Patient Advocate
Lawrence Charnas, MD, PhD
Lawrence Charnas, MD, PhD, is executive director of Clinical Research at the Rare Disease Research Unit of Pfizer. He is also clinical lead for the development of a recombinant immunomodulation drug candidate, not derived from blood, designed with the hope of meeting or exceeding the efficacy of the blood product Intravenous Immune Globulin (IVIg) in treating autoimmune diseases, including CIDP. Dr Charnas has 12 years of experience in pharmaceutical development in several rare diseases including several neuromuscular disorders. He received training in adult neurology at Johns Hopkins Hospital, medical and biochemical genetics at the National Institute of Child Health and Human Development, and pediatric neurology at the University of Minnesota.
Richard Lewis, MD
Cedars-Sinai Medical Center